TherapeuticsMD Inc

For the period ended Jun 30, 2024. Filed Aug 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 12, 2024

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(Unaudited - in thousands, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Revenue, net:
License and service revenue	$234	$437	$547	$853
Operating expenses:
Selling, general and administrative	1,233	2,781	2,555	5,837
Impairment of long-lived assets (Note 4)	1,261	—	1,261	—
Depreciation & amortization	180	128	313	155
Total operating expenses	2,674	2,909	4,129	5,992
Loss from operations	(2,440)	(2,472)	(3,582)	(5,139)
Other income (expense):
Interest expense and other financing costs	(5)	(45)	(5)	(95)
Miscellaneous income	1,395	103	1,728	510
Total other income, net	1,390	58	1,723	415
Loss from continuing operations before income taxes	(1,050)	(2,414)	(1,859)	(4,724)
Provision for income taxes	—	—	—	—
Loss from continuing operations, net of income taxes	(1,050)	(2,414)	(1,859)	(4,724)
(Loss) income from discontinued operations, net of income taxes	(40)	—	35	(1,293)
Net loss	$(1,090)	$(2,414)	$(1,824)	$(6,017)
Loss per common share, basic and diluted:
Continuing operations	(0.09)	(0.24)	(0.16)	(0.47)
Discontinued operations, net	(0.00)	—	0.00	(0.13)
Net loss per common share, basic and diluted	$(0.09)	$(0.24)	$(0.16)	$(0.60)
Weighted average common shares, basic	11,532	10,219	11,532	9,988
Weighted average common shares, diluted	11,532	10,219	11,532	9,988

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.